<DOC>
	<DOCNO>NCT00421044</DOCNO>
	<brief_summary>Patients participate core EPO2121 study clinically progress may participate extension protocol evaluate safety , tolerability , efficacy patupilone .</brief_summary>
	<brief_title>A Study Patupilone Patients With Advanced Solid Tumors Varying Degrees Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Completion core study require participation extension . 18 year age old World Health Organization ( WHO ) Performance Status score : 0 fully active less illness ; 1 carry heavy physical work , anything else ; 2 half day , look , well enough work . Life expectancy 3 month Patients measurable evaluable disease histologically document advanced solid tumor progress systemic therapy standard systemic therapy exist Severe and/or uncontrolled medical disease Known diagnosis human immunodeficiency virus ( HIV ) infection Presence active suspect acute chronic uncontrolled infection Severe cardiac insufficiency , uncontrolled and/or unstable cardiac coronary artery disease History another malignancy within 5 year prior study entry , except curatively treat nonmelanotic skin cancer cervical cancer situ Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>EPO</keyword>
	<keyword>Patupilone</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>